Literature DB >> 8695857

Sézary syndrome T-cell clones display T-helper 2 cytokines and express the accessory factor-1 (interferon-gamma receptor beta-chain).

R Dummer1, P W Heald, F O Nestle, E Ludwig, E Laine, S Hemmi, G Burg.   

Abstract

Sézary syndrome (SS) is a leukemic variant of low-grade cutaneous T-cell lymphomas (CTCLs). The clonal T cells in this lymphoproliferative disorder are poorly characterized. Using antibodies against the variable region of the T-cell receptor (TCR V alpha/beta), we identified four predominant T-cell clones (two V beta 8+ clones, one V beta 5.1+, and one V alpha 2(a)+) in peripheral blood mononuclear cells (PBMC) of SS patients. Their phenotype was CD3+, CD4+, CD5+, CD45RO+. Clonal T cells were purified, and cytokine transcription and secretion was analyzed by reverse transcriptase-polymerase chain reaction (RT-PCR) followed by hybridization with biotinylated probes and enzyme-linked immunosorbent assays (ELISAs). The interleukin-10 (IL-10) PCR product was cloned and sequenced and found to be identical to the published cDNA sequence. The presence of accessory factor-1 (AF-1, or interferon-gamma [IFN-gamma] receptor beta-chain) encoding mRNA was assessed by RT-PCR and immunostaining using serum of rabbits immunized with the extracellular domain of a recombinant human AF-1 protein followed by APAAP staining. Clonal T cells transcribe and secrete mainly T-helper 2 cytokines (IL-10, -5, and -13). mRNA from purified SS clones but not mRNA from SS total PBMC was positive for AF-1 in an agarose gel and/or after hybridization. AF-1 transcription was associated with membrane-bound immunoreactivity for AF-1 in SS clones. SS-derived T-cell clones display T-helper 2 cytokines. This weakens cell-mediated immunosurveillance, and explains the clinical and immunologic abnormalities in SS patients. The T-helper 2 cytokine spectrum of all clones investigated is associated with overexpression of AF-1. This suggests that AF-1 is a potential marker for these clones (and eventually other T-helper 2 lymphocytes) and might represent a target for treatment of the disease.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8695857

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  21 in total

1.  Primary cutaneous CD8-positive epidermotropic cytotoxic T cell lymphomas. A distinct clinicopathological entity with an aggressive clinical behavior.

Authors:  E Berti; D Tomasini; M H Vermeer; C J Meijer; E Alessi; R Willemze
Journal:  Am J Pathol       Date:  1999-08       Impact factor: 4.307

2.  Skin effector memory T cells do not recirculate and provide immune protection in alemtuzumab-treated CTCL patients.

Authors:  Rachael A Clark; Rei Watanabe; Jessica E Teague; Christoph Schlapbach; Marianne C Tawa; Natalie Adams; Andrew A Dorosario; Keri S Chaney; Corey S Cutler; Nicole R Leboeuf; Joi B Carter; David C Fisher; Thomas S Kupper
Journal:  Sci Transl Med       Date:  2012-01-18       Impact factor: 17.956

3.  Restoration of peripheral blood T cell repertoire complexity during remission in advanced cutaneous T cell lymphoma.

Authors:  Kei-ichi Yamanaka; Robert C Fuhlbrigge; Hitoshi Mizutani; Thomas S Kupper
Journal:  Arch Dermatol Res       Date:  2010-01-29       Impact factor: 3.017

Review 4.  Pruritus in cutaneous T-cell lymphoma: a review.

Authors:  Kristen Ahern; Elaine S Gilmore; Brian Poligone
Journal:  J Am Acad Dermatol       Date:  2012-01-30       Impact factor: 11.527

5.  Skin-derived interleukin-7 contributes to the proliferation of lymphocytes in cutaneous T-cell lymphoma.

Authors:  Kei-ichi Yamanaka; Rachael Clark; Benjamin Rich; Rebecca Dowgiert; Kazuki Hirahara; Daniel Hurwitz; Michio Shibata; Nina Mirchandani; David A Jones; Deborah S Goddard; Sara Eapen; Hitoshi Mizutani; Thomas S Kupper
Journal:  Blood       Date:  2005-12-01       Impact factor: 22.113

6.  Staphylococcal enterotoxins stimulate lymphoma-associated immune dysregulation.

Authors:  Thorbjørn Krejsgaard; Andreas Willerslev-Olsen; Lise M Lindahl; Charlotte M Bonefeld; Sergei B Koralov; Carsten Geisler; Mariusz A Wasik; Robert Gniadecki; Mogens Kilian; Lars Iversen; Anders Woetmann; Niels Odum
Journal:  Blood       Date:  2014-06-23       Impact factor: 22.113

Review 7.  Evolving insights in the pathogenesis and therapy of cutaneous T-cell lymphoma (mycosis fungoides and Sezary syndrome).

Authors:  Henry K Wong; Anjali Mishra; Timothy Hake; Pierluigi Porcu
Journal:  Br J Haematol       Date:  2011-08-25       Impact factor: 6.998

8.  Exploring the IL-21-STAT3 axis as therapeutic target for Sézary syndrome.

Authors:  Leslie van der Fits; Jacoba J Out-Luiting; Cornelis P Tensen; Willem H Zoutman; Maarten H Vermeer
Journal:  J Invest Dermatol       Date:  2014-04-22       Impact factor: 8.551

9.  Human skin is protected by four functionally and phenotypically discrete populations of resident and recirculating memory T cells.

Authors:  Rei Watanabe; Ahmed Gehad; Chao Yang; Laura L Scott; Jessica E Teague; Christoph Schlapbach; Christopher P Elco; Victor Huang; Tiago R Matos; Thomas S Kupper; Rachael A Clark
Journal:  Sci Transl Med       Date:  2015-03-18       Impact factor: 17.956

10.  Chromatin Accessibility Landscape of Cutaneous T Cell Lymphoma and Dynamic Response to HDAC Inhibitors.

Authors:  Kun Qu; Lisa C Zaba; Ansuman T Satpathy; Paul G Giresi; Rui Li; Yonghao Jin; Randall Armstrong; Chen Jin; Nathalie Schmitt; Ziba Rahbar; Hideki Ueno; William J Greenleaf; Youn H Kim; Howard Y Chang
Journal:  Cancer Cell       Date:  2017-06-15       Impact factor: 31.743

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.